Zanzalintinib vs Everolimus for Neuroendocrine Tumors
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial compares a new targeted therapy (zanzalintinib) with an existing drug (everolimus) for people with advanced neuroendocrine tumors (NETs). It aims to see which treatment works better and may offer a new option for patients whose cancer has grown despite previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of neuroendocrine tumor (NET) that started in your pancreas or elsewhere outside the pancreas, and it is well-differentiated (low to medium grade).
- Your cancer has grown or spread and cannot be removed by surgery.
- You have had scans (CT or MRI) in the last 12 months showing your cancer has gotten worse.
- You have at least one tumor that can be measured on scans.
- You have not taken a VEGFR-targeting TKI (like sunitinib) or an mTOR inhibitor (like everolimus) before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called Zanzalintinib for people with meningioma that has come back or grown despite past treatments. It aims to see if the drug can stop or slow tumor growth.
This trial compares two daily doses (5 mg vs 10 mg) of everolimus, a targeted therapy, to see which works better and is safer for people with advanced neuroendocrine tumors (NETs). You may qualify if your cancer has grown despite previous treatment and you are in relatively good health.
This trial tests a drug called zanzalintinib as a maintenance therapy to keep high-grade neuroendocrine tumors from growing after chemotherapy. It may be a good option if you've had success with chemotherapy and are ready for a treatment break.
This trial tests a new oral medication called zanzalintinib for adults with a rare type of tumor called pheochromocytoma or paraganglioma that has spread or cannot be removed with surgery. The goal is to see if this drug can slow or stop the tumor from growing, and to evaluate its safety.
This study tests cabozantinib, a targeted therapy that blocks tumor growth, in people with advanced neuroendocrine tumors who have already tried other treatments. It may offer a new option if your doctor plans to use this drug.
This trial tests a new drug combination for people with advanced clear cell kidney cancer that has gotten worse after initial immunotherapy treatment. The goal is to see if adding zanzalintinib to another immunotherapy can help control the cancer.
Hear when a new Pancreatic Neuroendocrine Tumor (pNET) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.